Resverlogix Corp.
  • About
    • Overview
    • Team
    • Partnership Strategy
    • Governance
  • Science & Programs
    • BETonMACE
    • Epigenetics
    • Apabetalone
    • Clinical
    • Publications
  • Investors
    • Financial Reports
    • News
    • Presentations & Events
    • Analysts
  • Articles & Media
    • Featured Stories
    • From the Archives
  • Contact
    • General
    • Careers
RVX $0.96 +$0.05

Investors

  1. Home
  2. Investors
  3. News

News

To receive future news releases direct to your inbox, subscribe by emailing ir@resverlogix.com.

Historical news and financial information can also be found at www.sedar.com under the Company’s profile.

2021 2020 2019 2018 2017 2016 2015 2014
New Published Evidence of Apabetalone’s Beneficial Effects on COVID-19
March 3, 2021
Resverlogix Reschedules Update Webcast and Conference Call
January 27, 2021
Resverlogix Announces Update Webcast and Conference Call
January 18, 2021
Apabetalone’s Positive Effect on Hospitalized Patients Involving Heart Failure
January 12, 2021
  • Financial Reports
  • News
  • Presentations & Events
  • Analysts
Fact Sheet Request Info Presentation
About
  • Overview
  • Team
  • Partnership Strategy
  • Governance
Science & Programs
  • BETonMACE
  • Epigenetics
  • Apabetalone
  • Clinical
  • Publications
Investors
  • Financial Reports
  • News
  • Presentations & Events
  • Analysts
Articles & Media
  • Featured Stories
  • From the Archives
Contact
  • General
  • Careers
  • Contact
  • Glossary
  • Sitemap
  • Legal